Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERMAID-1: Durvalumab plus chemotherapy in completely resected stage II–III NSCLC
jRCT2080225282Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab arm with Placebo arm (2 arms). Started Jul 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225282.